Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study

British Journal of Cancer

Volumn 98, Issue 4, 2008, Pages 728-733

  Mellemkjaer L ^a   Dahl, C ^b   Olsen, J H ^a   Bertelsen, L ^a   Guldberg, P ^b   Christensen, J ^a   Børresen Dale, Anne Lise ^t   Stovall, Marilyn ^e   Langholz, B ^f   Bernstein, Leslie ^o   Lynch, C F ^g   Malone, K E ^h   Haile, R W ^f   Andersson, M ⁱ   Thomas, D C ^f   Concannon, P ^j   Capanu, Marinela ^k   Boice Jr , J D ^l,m   Bernstein, Jonine L ^k   Olsen, Jørgen H ^b   Borg, Åke ^t   Bertelsen, Lisbeth ^b   Mellemkjær, Lene ^b   Guldberg, Per ^b   Liang, Xiaolin ^k   Wolitzer, Abigail ^k   Seminara, Daniela ⁿ   Haile, Robert W ^o   Diep, Anh T ^o   Zhou, Nianmin ^o   Liu, Yong ^o   Ter Karapetova, Evgenia ^o   Hernandez, Andre ^o   Orlow, Irene ^k   Donnelly Allen, Laura ^o   Lynch, Charles F ^g   DeWall, Jeanne ^g   Malone, Kathleen E ^h   Epstein, Noemi ^h   Anton Culver, Hoda ^p   Largent, Joan ^p   Smith, Susan ^e   Shore, Roy E ^q   Boice Jr , John D ^l,r   Langholz, Bryan M ^o   Thomas, Duncan C ^o   Thompson, W Douglas ^s   Begg, Colin ^k   more..

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j UNIVERSITY OF VIRGINIA   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^m VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

^o UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q NEW YORK UNIVERSITY   (United States)

^r VANDERBILT UNIVERSITY   (United States)

^s UNIVERSITY OF SOUTHERN MAINE   (United States)

^t New York University ^*

more..

Author keywords

1100delC mutation; Asynchronous contralateral breast cancer; CHEK2; Chemotherapy; Genes; Radiation therapy

Indexed keywords

CHECKPOINT KINASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CHEK2 GENE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FAMILY HISTORY; FEMALE; GENE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; PRIORITY JOURNAL;

EID: 39449090355     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604228     Document Type: Article

References (22)

1. Baeyens A, Claes K, Willems P, De Ruyck K, Thierens H, Vral A (2005) Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation. Cancer Genet Cytogenet 163: 106-112
2. Bartkova J, Guldberg P, Gronbaek K, Koed K, Primdahl H, Moller K, Lukas J, Orntoft TF, Bartek J (2004) Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 23: 8545-8551
3. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL (2008) Variation of breast cancer risk among BRCA1/2 carriers: an investigation by the WECARE study group. JAMA 299: 194-201
4. Bernstein JL, Langholz B, Haile RW, Bernstein L, Thomas DC, Stovall M, Malone KE, Lynch CF, Olsen JH, Anton-Culver H, Shore RE, Boice Jr JD, Berkowitz GS, Gatti RA, Teitelbaum SL, Smith SA, Rosenstein BS, Borresen-Dale AL, Concannon P, Thompson WD (2004) Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res 6: R199-R214
5. Bernstein JL, Teraoka SN, John EM, Andrulis IL, Knight JA, Lapinski R, Olson ER, Wolitzer AL, Seminara D, Whittemore AS, Concannon P (2006) The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev 15: 348-352
6. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FBL, Schmidt MK, Klijn JGM, Russell NS, van Leeuwen FE, van't Veer LJ (2007) Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res 9: R26
7. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, Van Leeuwen FE, Russell NS, van't Veer LJ (2004) Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 83: 91-93
8. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74: 1175-1182
9. Chekmariova EV, Sokolenko AP, Buslov KG, Iyevleva AG, Ulibina YM, Rozanov ME, Mitiushkina NV, Togo AV, Matsko DE, Voskresenskiy DA, Chagunava OL, Devilee P, Cornelisse C, Semiglazov VF, Imyanitov EN (2006) CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res Treat 100: 99-102
10. de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG (2004) Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 41: 731-735
11. Friedrichsen DM, Malone KE, Doody DR, Daling JR, Ostrander EA (2004) Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Breast Cancer Res 6: R629-R635
12. Huzarski T, Cybulski C, Domagala W, Gronwald J, Byrski T, Szwiec M, Woyke S, Narod SA, Lubinski J (2005) Pathology of breast cancer in women with constitutional CHEK2 mutations. Breast Cancer Res Treat 90: 187-189
13. Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, Lukas J, Blomqvist C, Holli K, Heikkila P, Sauter G, Kallioniemi OP, Bartek J, Nevanlinna H (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113: 575-580
14. Kwiatkowska E, Skasko E, Niwinska A, Wojciechowska-Lacka A, Rachtan J, Molong L, Nowakowska D, Konopka B, Janiec-Jankowska A, Paszko Z, Steffen J (2006) Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland. Neoplasma 53: 305-308
15. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55-59
16. Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25: 5912-5919
17. Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P (2003) The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 63: 8153-8157
18. Osorio A, Rodriguez-Lopez R, Diez O, de la Hoya M, Martinez JI, Vega A, Esteban-Cardenosa E, Alonso C, Caldes T, Benitez J (2004) The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer 108: 54-56
19. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ (2007) Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2* 1100delC germline mutation. J Clin Oncol 25: 64-69
20. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71: 432-438
21. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG (2007) Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 25: 57-63
22. Wu X, Webster SR, Chen J (2001) Characterization of tumor-associated Chk2 mutations. J Biol Chem 276: 2971-2974